利那洛肽胶囊联合低剂量聚乙二醇电解质散用于结肠镜肠道准备的可行性与安全性

doi:10.3877/cma.j.issn.2095-7157.2022.03.001

中华胃肠内镜电子杂志 ›› 2022, Vol. 09 ›› Issue (03) : 121 -125. doi: 10.3877/cma.j.issn.2095-7157.2022.03.001

论著

利那洛肽胶囊联合低剂量聚乙二醇电解质散用于结肠镜肠道准备的可行性与安全性

于晓欢¹, 路璐², 赵振峰², 谢长访², 熊英³^,^†(

)

^1. 067000　承德，河北承德医学院；071000　保定，河北保定市第一中心医院内镜诊疗中心；071000　保定，河北保定市第一中心医院消化内三科
^2. 071000　保定，河北保定市第一中心医院内镜诊疗中心
^3. 071000　保定，河北保定市第一中心医院内镜诊疗中心；071000　保定，河北保定市第一中心医院消化内三科；河北省分子病理与肿瘤早期诊断重点实验室

收稿日期:2022-07-08 出版日期:2022-08-15
通信作者: 熊英
基金资助:
保定市科技计划项目(2141ZF248)

Feasibility and safety of linaclotide combined with low dose polyethylene glycol as intestinal cleanser

Xiaohuan Yu¹, Lu Lu², Zhenfeng Zhao², Changchuan Xie², Ying Xiong³^,^†()

^1. Chengde Medical College, Chengde 067000, China; Endoscopy Center, No.1 Central Hospital of Baoding, Hebei Baoding 071000, China; Digestive Department, No.1 Central Hospital of Baoding, Hebei Baoding 071000, China
^2. Endoscopy Center, No.1 Central Hospital of Baoding, Hebei Baoding 071000, China
^3. Endoscopy Center, No.1 Central Hospital of Baoding, Hebei Baoding 071000, China; Digestive Department, No.1 Central Hospital of Baoding, Hebei Baoding 071000, China; Key Laboratory of Molecular Pathology and Early Diagnosis of Tumors in Hebei Province, Baoding 071000, Hebei, China

Received:2022-07-08 Published:2022-08-15
Corresponding author: Ying Xiong

全文 ( ) 下载PDF ( ) 导出引用

引用本文：

于晓欢, 路璐, 赵振峰, 谢长访, 熊英. 利那洛肽胶囊联合低剂量聚乙二醇电解质散用于结肠镜肠道准备的可行性与安全性[J]. 中华胃肠内镜电子杂志, 2022, 09(03): 121-125.

Xiaohuan Yu, Lu Lu, Zhenfeng Zhao, Changchuan Xie, Ying Xiong. Feasibility and safety of linaclotide combined with low dose polyethylene glycol as intestinal cleanser[J]. Chinese Journal of Gastrointestinal Endoscopy(Electronic Edition), 2022, 09(03): 121-125.

目的

探讨利那洛肽胶囊联合低剂量复方聚乙二醇电解质散(PEG)作为肠镜检查前肠道清洁剂的可行性与安全性。

方法

选取2022年3月至2022年5月经保定市第一中心医院门诊拟行肠镜检查的300例受试者作为研究对象。采用随机数字表，将受试者随机分为三组，每组各100例患者。A组作为对照组单用3盒PEG、B组利那洛肽胶囊2粒(290 μg/每粒)联合2盒PEG清肠、C组3粒利那洛肽胶囊联合2盒PEG清肠，比较三组患者肠道清洁程度及不良事件的发生率。

结果

B组左半结肠、横结肠、右半结肠及总Boston肠道准备量表(BBPS)均与A组差异无统计学意义(P>0.05)；C组左半结肠、横结肠、右半结肠及总BBPS均高于A组，具有统计学意义(P<0.05)，B组的左半结肠、横结肠、右半结肠及总BBSP评分均低于A组，具有统计学意义(P<0.05)。不良事件发生率方面，B、C组均低于A组，差异有统计学意义(P<0.05)。B、C组之间差异无统计学意义(P>0.05)。

结论

利那洛肽胶囊2粒联合2盒PEG肠道清洁度与单用3盒PEG相似，利那洛肽胶囊3粒联合2盒PEG清肠效果优于单用3盒PEG。2种联合用药方式不良事件发生率均低于单用3盒PEG。

关键词: 肠道准备, 复方聚乙二醇电解质散, 利那洛肽胶囊

Objective

To investigate the feasibility and safety of linaclotide capsule combined with low-dose compound polyethylene glycol electrolyte powder (PEG) as intestinal detergent before colonoscopy.

Methods

A total of 300 subjects who planned to undergo colonoscopy in the outpatient department of Baoding First Central Hospital from March 2022 to May 2022 were selected as the research objects. The subjects were randomly divided into three groups with 100 patients in each group by random number table. Group A was treated with 3 boxes of PEG alone, group B with 2 boxes of linaclotide capsules (290 μg/capsules) combined with 2 boxes of PEG intestinal cleanse, and group C with 3 boxes of linaclotide capsules combined with 2 boxes of PEG intestinal cleanse. The degree of intestinal cleanliness and the incidence of adverse events were compared among the three groups.

Results

There were no significant differences in left colon, transverse colon, right colon and total Boston bowel Preparation Scale (BBPS) between group B and group A (P> 0.05). The left colon, transverse colon, right colon and total BBPS of group C were higher than those of group A, with statistical significance (P< 0.05). The left colon, transverse colon, right colon and total BBSP scores of group B were lower than those of group A, with statistical significance (P< 0.05). The incidence of adverse events in groups B and C was lower than that in group A, and the difference was statistically significant (P< 0.05). There was no significant difference between groups B and C (P> 0.05).

Conclusion

The intestinal cleanliness of 2 linaclotide capsules combined with 2 boxes of PEG is similar to that of 3 boxes of PEG alone. The intestinal cleansing effect of 3 linaclotide capsules combined with 2 boxes of PEG is better than that of 3 boxes of PEG alone. The incidence of adverse events was lower in the two drug combinations than in the three-box PEG alone.

Key words: Intestinal preparation, Compound polyethylene glycol electrolyte powder, Linaclotide

表1 三组患者一般资料比较

组别	例数	年龄(岁，±s)	性别(男/女，例)
A组	100	52.50±13.09	56/44
B组	100	50.74±11.54	48/52
C组	100	49.32±13.75	58/42
F/χ²值		0.525	2.254
P值		0.592	0.324

表1 三组患者一般资料比较

组别	例数	年龄(岁，±s)	性别(男/女，例)
A组	100	52.50±13.09	56/44
B组	100	50.74±11.54	48/52
C组	100	49.32±13.75	58/42
F/χ²值		0.525	2.254
P值		0.592	0.324

表2 三组患者肠道清洁度的BBSP评分表(±s)

组别	例数	左边结肠及评分	横结肠及评分	右半结肠及评分	总评分
A组	100	2.41±0.494	2.31±0.465	2.03±0.521	6.75±0.999
B组	100	2.48±0.502^a	2.35±0.479^a	2.06±0.422^a	6.89±1.091^a
C组	100	2.62±0.488^b	2.61±0.490^bc	2.20±0.532^bc	7.43±0.913^bc
F值		4.670	11.601	3.371	12.805
P值		0.010	0.001	0.036	0.001

表2 三组患者肠道清洁度的BBSP评分表(±s)

组别	例数	左边结肠及评分	横结肠及评分	右半结肠及评分	总评分
A组	100	2.41±0.494	2.31±0.465	2.03±0.521	6.75±0.999
B组	100	2.48±0.502^a	2.35±0.479^a	2.06±0.422^a	6.89±1.091^a
C组	100	2.62±0.488^b	2.61±0.490^bc	2.20±0.532^bc	7.43±0.913^bc
F值		4.670	11.601	3.371	12.805
P值		0.010	0.001	0.036	0.001

表3 三组患者不良事件发生率的比较(例)

组别	恶心	呕吐	腹胀	总不良事件
A组	26	10	15	51
B组	13^a	6^a	6^a	25^a
C组	12^b	6^b	5^b	23^b
χ²值	8.646	6.593	7.664	22.071
P值	0.013	0.037	0.220	<0.01

表3 三组患者不良事件发生率的比较(例)

组别	恶心	呕吐	腹胀	总不良事件
A组	26	10	15	51
B组	13^a	6^a	6^a	25^a
C组	12^b	6^b	5^b	23^b
χ²值	8.646	6.593	7.664	22.071
P值	0.013	0.037	0.220	<0.01

[1]	Johnson David A, Barkun Alan N, Cohen Larry B，et al. Optimizing adequacy of bowel cleansing for colonoscopy: recommendations from the US multi-society task force on colorectal cancer[J]．Gastroenterology, 2014, 147(4): 903-924.
[2]	中国医师协会内镜医师分会消化内镜专业委员会，中国抗癌协会肿瘤内镜学专业委员会. 中国消化内镜诊疗相关肠道准备指南(2019，上海)[J]. 中华消化内镜杂志，2019，36(7):457-469.
[3]	Kluge MA, Williams JL, Wu CK. Inadequate Boston Bowel Preparation Scale scores predict the risk of missed neoplasia on the next colonoscopy[J]．Gastrointest Endosc，2018，87(3):744-751.
[4]	Kang X, Zhao L, Zhu Z, et al. Same-Day Single Dose of 2 Liter Polyethylene Glycol is Not Inferior to The Standard Bowel Preparation Regimen in Low-Risk Patients: A Randomized, Controlled Trial[J]．Am J Gastroenterol，2018，113(4):601-610.
[5]	Bitoun A, Ponchon T, Barthet M, et al. Results of a prospective randomised multicentre controlled trial comparing a new 2-L ascorbic acid plus polyethylene glycol and electrolyte solution vs. sodium phosphate solution in patients undergoing elective colonoscopy[J]．Aliment Pharmacol Ther，2006，24(11-12):1631-1642.
[6]	中国医师协会内镜医师分会消化内镜专业委员会，中国抗癌协会肿瘤内镜学专业委员会. 中国消化内镜诊疗相关肠道准备指南(2019，上海)[J]. 中华消化内镜杂志，2019，36(7):457-469.
[7]	Chamberlain SM, Rao SS. Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome[J]．Expert Opin Drug Saf，2012，11(5):841-850.
[8]	都贤，时晓冬，牛巍巍，等. 2019欧洲胃肠道内镜学会结肠镜检查肠道准备指南解读[J]. 河北医科大学学报，2020，41(4):373-376.
[9]	杨栋，陶克，李梦，等. 电子结肠镜进镜操作难度的相关因素研究[J/CD]. 中华胃肠内镜电子杂志，2022，9(1):30-35.
[10]	Kuhn M. Molecular Physiology of Membrane Guanylyl Cyclase Receptors[J]．Physiol Rev，2016，96(2):751-804.
[11]	Góngora-Benítez M, Tulla-Puche J, Albericio F. Constella™(EU)-Linzess™(USA): the last milestone in the long journey of the peptide linaclotide and its implications for the future of peptide drugs[J]．Future Med Chem，2013，5(3):291-300.
[12]	Busby RW, Kessler MM, Bartolini WP, et al. Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation[J]．J Pharmacol Exp Ther，2013，344(1):196-206.
[13]	Busby RW, Bryant AP, Bartolini WP, et al. Linaclotide，throughactivation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit[J]．Eur J Pharmacol，2010，649(1-3):328-335.
[14]	李彦楠，杨丽旋，赵钟辉，等. 《2020年中国肠易激综合征专家共识意见》解读[J]. 中国临床医生杂志，2021，49(10):1151-1155.
[15]	Zhang M, Zou W, Xu C, et al. Polyethylene glycol combined with linaclotide is an effective and well-tolerated bowel preparation regimen for colonoscopy: an endoscopist-blinded, randomized, controlled trial [J]．Eur J Gastroenterol Hepatol，2021，33(1S Suppl 1):e625-e633.
[16]	Guo R, Wang YJ, Liu M, et al. The effect of quality of segmental bowel preparation on adenoma detection rate[J]．BMC Gastroenterol，2019，19(1):119.
[17]	葛伏林，吴文娟，王鸣，等. 硫酸镁溶液不同口服方法在老年人肠道准备中的应用效果及安全性分析[J/CD]．中华胃肠内镜电子杂志，2021，8(2):68-71.

[1]	李世红, 牛钦王, 刘雁军, 张元川, 刘展. 术前未行肠道准备对择期结直肠手术影响的探讨[J]. 中华普通外科学文献(电子版), 2021, 15(04): 278-281.
[2]	杨晓亮, 颜璟, 吴艳军, 岳晓林, 邱体红, 刘培根, 杨映弘. 结直肠癌术前机械性肠道准备的可行性分析[J]. 中华普通外科学文献(电子版), 2018, 12(05): 337-341.
[3]	李肆柱, 贾恒, 张溪, 訾维, 王文刚, 孙鹏进, 杨威. 机械性肠道准备在结直肠手术的临床应用价值研究[J]. 中华普外科手术学杂志(电子版), 2020, 14(05): 464-467.
[4]	陈佳楠, 陈海鹏, 王玲玲, 刘正, 刘骞. 首荟通便胶囊在右半结肠切除手术肠道准备中的作用研究[J]. 中华结直肠疾病电子杂志, 2021, 10(05): 476-481.
[5]	杨龙宝, 赵刚, 安苗, 秦赟, 薛琼, 王进海, 董蕾. 联合无痛胃肠镜检查患者的肠道准备策略[J]. 中华结直肠疾病电子杂志, 2021, 10(03): 278-283.
[6]	顾君君, 赵子夜, 韩文军, 吴琴, 王苗, 陈佳, 杨婷, 于恩达. 日间病房结直肠息肉切除患者的肠道准备质量现状调查[J]. 中华结直肠疾病电子杂志, 2020, 09(06): 576-580.
[7]	于华隆, 胡金晨, 姜立新. 从历史角度看结直肠术前肠道准备争议[J]. 中华结直肠疾病电子杂志, 2019, 08(05): 505-508.
[8]	温艳清, 马海英, 张旭. 普芦卡必利用于老年结肠镜前肠道准备的效果及干预时长观察[J]. 中华结直肠疾病电子杂志, 2017, 06(06): 494-497.
[9]	孔绘敏, 王秀勤, 梁海. 硫酸镁钠钾口服液与复方聚乙二醇电解质散对患者肠道清洁的对比研究[J]. 中华消化病与影像杂志(电子版), 2023, 13(04): 259-261.
[10]	吕小燕, 宋建华, 王莉, 方衍锋. 肠道准备对无痛胃镜黏膜清晰度和安全性的影响[J]. 中华消化病与影像杂志(电子版), 2020, 10(02): 66-69.
[11]	徐向迎, 宗晶, 梁艳. 流程化护理干预在聚乙二醇肠道准备患者中的应用[J]. 中华消化病与影像杂志(电子版), 2019, 09(05): 220-221.
[12]	叶彬, 王昌成, 韩成艳, 刘树青, 梁凤. 莫沙必利联合二甲硅油散在慢性便秘患者结肠镜检查肠道准备中的应用[J]. 中华消化病与影像杂志(电子版), 2019, 09(05): 203-207.
[13]	叶淑君, 刘阳, 马连君. 肠道准备与结肠息肉检出率的研究进展[J]. 中华胃肠内镜电子杂志, 2022, 09(02): 104-107.
[14]	葛伏林, 吴文娟, 王鸣, 徐杰, 胡倩, 董晓宇, 万军. 硫酸镁溶液不同口服方法在老年人肠道准备中的应用效果及安全性分析[J]. 中华胃肠内镜电子杂志, 2021, 08(02): 68-71.
[15]	中华医学会消化内镜学分会儿科协作组, 中国医师协会内镜医师分会儿科消化内镜专业委员会. 中国儿童消化内镜诊疗相关肠道准备快速指南(2020,西安)[J]. 中华胃肠内镜电子杂志, 2021, 08(01): 1-12.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Feasibility and safety of linaclotide combined with low dose polyethylene glycol as intestinal cleanser

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Feasibility and safety of linaclotide combined with low dose polyethylene glycol as intestinal cleanser